Catalog No.
RVV02801
Expression system
Mammalian Cells
Species reactivity
HRSV-A
Host species
Human
Isotype
IgG1
Clonality
Monoclonal
Applications
ELISA, IHC, WB
Recommended Dilution
| Application |
Dilution |
| ELISA |
1:4000-1:8000, IHC: 1:50-1:200, WB: 1:1000-1:5000 |
Target
F,Fusion glycoprotein F0
Concentration
1.48 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03420
Form
Liquid
Storage buffer
100 mM Pro-Ac, 20 mM Arg, pH 5.0
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Am14
Note
For research use only.
A Self-Assembled RSV-DS2 Based Nanovaccine Elicits a Strong Immune Response Against Respiratory Syncytial Virus Infection. [RVV02801]
Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization., PMID:2251875
Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage., PMID:1375280
Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic., PMID:11277694
Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection., PMID:29029312
Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response., PMID:33574352
Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine. [RVV02801]
Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice. [RVV02801]
For research use only. Not for human or drug use.
